Loading patent…
AssigneeGenentech, Inc.
InventorsAmy Dressen, David B. Iaea, Moulay Hicham Alaoui Ismaili, Janet K. Jackman, Robert A. Lazarus, Kelly Michele Loyet, Henry R. Maun, Brian Louis Yaspan, Tangsheng Yi, Joseph R. Arron, Hilda Y Hernandez-Barry
Estimating the term…
Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Sydrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.
A method for treating asthma in a subject comprising administering an effective amount of a KLK5 antagonist to the subject, wherein the KLK5 antagonist is a SPINK Fc fusion polypeptide.
(canceled)
A method of selecting a subject suffering from asthma for a treatment comprising a KLK5 antagonist, comprising determining the presence or absence of a genetic variation located in the KLK5 genomic sequence in a biological sample from the subject, wherein the presence of the genetic variation indicates that the subject is suitable for treatment with a KLK5 antagonist.
A method for detecting the presence or absence of a genetic variation in the KLK5 genomic sequence indicating that a subject suffering from asthma is suitable for treatment with a KLK5 antagonist, comprising:
-9. (canceled)
-24. (canceled)
-31. (canceled)
-45. (canceled)
Dependencies are inferred from the claim text.